Epstein-Barr virus latent membrane protein 2 peptide–Major Histocompatibility Complex (EBV LMP2-MHC)

The Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide–Major Histocompatibility Complex (MHC) is a critical target for immunotherapy in EBV-associated malignancies. LMP2 is a viral protein expressed during EBV latency types II and III, which are characteristic of nasopharyngeal carcinoma, Hodgkin lymphoma, and certain gastric cancers (Source: Journal of Virology, PMID: 15141001). Within the host cell, LMP2 is processed into short peptide fragments that are subsequently presented on the cell surface by MHC class I molecules, most frequently HLA-A*02:01 (Source: Blood, PMID: 10807785). Because these complexes are exclusively found on EBV-infected cells and not on healthy tissues, they serve as highly specific neoantigen-like targets for T-cell receptor (TCR) engineered T-cells and TCR-like antibodies (Source: Clinical Cancer Research, PMID: 29158373). Therapeutic intervention typically involves adoptive T-cell transfer or bispecific molecules designed to recognize the specific peptide-MHC configuration, leading to the targeted destruction of the tumor cell. However, the efficacy of targeting this complex can be limited by viral mechanisms that downregulate MHC expression or by the immunosuppressive microenvironment of the tumor (Source: Frontiers in Immunology, PMID: 30305453).

Other names

LMP2-HLA complexEBV LMP2 peptide-HLA-A*02:01 complexLatent membrane protein 2-MHC class I complexEBV LMP2-pMHC

T-cell receptor-mediated cytotoxicity via recognition of viral peptide-MHC complexes, leading to apoptosis of EBV-infected cells.